Tokyo, Japan, October 30, 2024 — At Chariloto Co., Ltd., a consolidated subsidiary of MIXI, Inc., suspicions have come to light that its representative director and one employee engaged in improper fund transfers with a business partner.

We deeply regret that this situation has occurred, and we sincerely apologize to our shareholders, investors, business partners, and all other stakeholders for the significant inconvenience and concern this has caused.

We recognize this matter as a serious issue at the relevant consolidated subsidiary, and we are proceeding with an investigation into the facts. We will also analyze the causes and formulate measures to prevent recurrence. We will promptly disclose any facts that should be made public as soon as they are confirmed through the investigation.

Today, based on information obtained from Hiroo Ueda, the Representative Director of the consolidated subsidiary in question, and other relevant information, the company resolved at an Extraordinary General Meeting of Shareholders to dismiss him as a director, and he was removed from his position as director effective today. We hereby announce the details as follows.

1.Reason for the Change in Representative Director of the Consolidated Subsidiary (Dismissal)

We take the occurrence of this concern seriously, and based on the information obtained from the individual concerned and other relevant facts, a resolution was passed at an extraordinary general meeting of shareholders of the consolidated subsidiary to dismiss the director, who was removed from the position effective today.

2.Change (Dismissal) of Representative Director of the Consolidated Subsidiary:

　(Dismissal)
　Name: Hiroo Ueda
　Title: Representative Director
　Dismissal Date: October 30, 2024

Accordingly, Yosuke Ishihara, who is seconded from our company and serves as a director of the consolidated subsidiary in question, will assume the position of Representative Director.

We are working to disclose the facts of this matter in our FY2025 Q2 financial results briefing scheduled for Friday, November 8, 2024, and we will announce measures to prevent recurrence as soon as they are finalized.